WT1 gene, originally identified as a tumor suppressor involved in the formation of Wilms' tumor of the kidney, was subsequently described to have an oncogenic role in a variety of tumors from different origins, including leukemias. 1 In comparison to normal progenitor cells, it is overexpressed in acute lymphoblastic and myeloblastic leukemia, and in the blast crisis phase of chronic myelogenous leukemia; 1,2 high levels of the protein are associated with a poor response to therapy. 1, 3 WT1 knockdown by antisense oligonucleotides or RNA interference was shown to induce apoptosis; conversely, its overexpression in myeloid leukemia cells protected against cell death. Modulation of some members of the bcl-2 family has been associated with apoptosis inhibition by WT1. 1, 3 Among proteins that regulate apoptosis in leukemia cells, a role is assigned to BAG3, a member of the family of proteins that, through their BAG domain, interact with HSC70/HSP70 heat shock proteins. bag3 gene expression is constitutive in some tumor types, including leukemias; in these cells, BAG3 protein has been shown to sustain cell survival and downmodulate cell apoptotic response to drugs, by either HSP70-dependent or -independent mechanisms. [4] [5] [6] [7] Here we report that WT1 induces bag3 gene expression. This finding identifies a novel target of WT1 protein involved in apoptosis regulation in leukemia cells.
As using in silico analysis we had found two putative WT1 binding sites on the bag3 promoter, we decided to investigate whether WT1 is directly recruited onto the bag3 promoter using a chromatin immunoprecipitation assay (ChIP) in K562 cells, which express significant amounts of endogenous WT1 and BAG3. Chromatin was immunoprecipitated with anti-WT1 antibodies. Subsequent PCR analysis, performed using oligonucleotides covering the putative WT1 binding sites, revealed that WT1 bound to the bag promoter sequences (350-bp band), whereas rabbit IgG antibody controls did not (Figure 1a) . WT1 protein has two major isoforms, designated WT1(-KTS) and WT1(+KTS), containing an extra three aminoacids (KTS) between the third and fourth zinc fingers; WT1(ÀKTS) appears to exert its effect mainly as a transcriptional factor, whereas WT1( þ KTS) is involved in RNA processing. 1 To investigate the transcriptional modulation of bag3 promoter by WT1, we introduced a luciferase reporter plasmid containing the bag3 promoter into HEK293 cells and analyzed luciferase levels in the presence of increasing amounts of WT1(ÀKTS) or WT1( þ KTS) expression plasmids. As shown in Figure 1b , the 'transcriptional isoform', WT1(ÀKTS), enhanced bag3 promoter activity in a dose-dependent manner, whereas transfection of the 'posttranscriptional isoform', WT1( þ KTS), did not influence the transcriptional activity.
To assess whether forced expression of WT1 isoforms could modulate endogenous bag3, we transfected HEK293 cells with increasing concentrations of the expression vectors encoding WT1(ÀKTS) or WT1( þ KTS) and evaluated bag3 mRNA and BAG3 protein levels by quantitative real-time-PCR and western blot analyses, respectively. We observed a progressive increase in the levels of bag3 RNA and BAG3 protein in cells transfected with increasing amount of WT1(ÀKTS), and not in those transfected with WT1( þ KTS) (Figures 1c-d) , confirming the transcriptional activation of endogenous bag3 gene by WT1.
To provide a further argument for bag3 regulation by WT1, we evaluated bag3 expression in K562 cells following small interfering RNA (RNAi)-mediated knockdown of WT1. As shown in Figure 1e , the levels of bag3 mRNA in WT1 knockdown cells were decreased by about 40%; western blotting confirmed downmodulation of BAG3 protein.
Altogether, these observations ascribe a role to WT1 in bag3 gene regulation.
We next evaluated the effect of WT1 silencing on apoptosis. In K562 cells treated with the proapoptotic agent phenethyl isothiocyanate (PEITC), WT1 silencing significantly enhanced apoptosis, as assessed by flow cytometry, with respect to control scrambled RNA (Figure 2a ). Conversely, BAG3 protein appeared to exert an antiapoptotic effect against PEITC treatment, since its overexpression obtained by cell transduction with a bag3 cDNA-carrying adenovirus (AdhBAG3) downmodulated PEITC-induced apoptosis (Figure 2b ). We therefore investigated whether the enhancement of apoptosis induced by WT1 knockdown was reversed by bag3 overexpression. Indeed, in cells infected by AdhBAG3, cell survival was rescued by more than 25% compared to cells treated with WT1 RNAi alone (Figure 2a) . Therefore, WT1 inhibition of apoptosis appeared to be in part mediated by BAG3 protein.
The above-reported findings show that WT1 protein regulates bag3 expression and that WT1-mediated increase in BAG3 protein levels contributes to the prosurvival role of WT1 in leukemic cells. The identification of bag3 as a target gene of WT1 improves our understanding of apoptosis regulation by this factor. We believe that the associated impacts of BAG3 and WT1 in leukemia cell survival and response to therapy deserve further investigation.
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This work was supported in part by funds of Italian Ministry of University and Research (MIUR). Cruz, CA, USA), as described, 8 or with nonspecific IgGs as control. The resultant samples were analyzed by standard PCR using specific bag3 primers (forward: 5 0 -tcggcgcaaaggagaggga-3 0 ; reverse: 5 0 -ggccagttgctacctccct-3 0 ). As a negative control, PCR was performed using GAPDH-specific primers (forward: 5 0 -aggtcatccatgacaactttgg-3 0 ; reverse: 5 0 -ttgtcataccaggaaatgagct-3 0 ). Schematic representation of the bag3 promoter region that contains the WT1 DNA-binding sites is reported in the lower part of the panel. (b) HEK293 cells were transiently transfected using Lipofectamine Reagent (Invitrogen, Carlsbad, CA, USA) in six-well plates with 0.2 mg of a luciferase reporter plasmid containing bag3 promoter and 0.25, 0.5 or 0.7 mg of WT1(ÀKTS) or WT1( þ KTS) expression plasmid. The Dual-Luciferase Reporter Assay (Promega Corporation, Madison, WI, USA) was performed 24h after the transfection. Bar graphs depict the means of fold increase of transcription activities with respect to bag3 promoter activity (triplicate determinations). WT1(ÀKTS) and WT1( þ KTS) protein overexpression was evaluated by western blot analysis and GAPDH was used as loading control. (c) HEK293 cells were transiently transfected using Lipofectamine Reagent (Invitrogen) in six-well plates with 0.5, 1 or 2 mg of a WT1(ÀKTS) or WT1( þ KTS) expression plasmid. At 48 h after transfection, total RNA was isolated using TRIzoL reagent (Invitrogen) and cDNA was synthesized from 1 mg of each RNA using MMLV reverse transcriptase (Invitrogen). RNA levels were measured by real-time PCR in a Bio-Rad iCycler using Master Mix (Bio-Rad, Berkeley, CA, USA) and specific primers for bag3 or b-actin (forward: 5 0 -cgacaggatgcagaaggaga-3 0 ; reverse: 5 0 -cgtcatactcctgcttgcttgctg-3 0 ), respectively. Standard deviations were calculated from triplicate measurements. (d) HEK293 cells were treated as described in (c); total protein lysates were obtained and resolved by 10% SDS-PAGE gels and were immunoblotted. Extracts were analyzed for their content of BAG3 protein in western blotting using a polyclonal anti-BAG3 antibody (TOS-2; Enzo Biochem, New York, NY, USA). An antibody recognizing b-actin was used to monitor equal loading conditions. (e) K562 cells were transiently transfected using Lipofectamine 2000 Reagent (Invitrogen) with 2 mg of a short interfering RNA plasmid (RNAi) to silence WT1, or 2 mg of a scrambled RNA; after 48 h cell RNA and total protein extracts were prepared. RNA levels were measured by real-time PCR in a Bio-Rad iCycler using Master Mix (Bio-Rad) and primers specific for WT1, bag3 or b-actin. Proteins were analyzed by western blot analysis using anti-WT1 and anti-BAG3 (TOS-2) antibodies. Anti b-actin antibody was used as control. Multiple myeloma (MM) is a relatively common hematological malignancy characterized by the presence of lytic bone disease. 1 As part of the staging procedures of newly diagnosed myeloma, the skeletal survey is mandatory, while bone marrow magnetic resonance imaging (MRI) can give complementary information and is recommended for patients with normal conventional radiographs.
2 MRI is very sensitive in detecting bone marrow involvement. 3 Four MRI patterns of marrow involvement in myeloma have been recognized: (1) normal appearance of bone marrow despite minor microscopic plasma cell infiltration, (2) focal involvement, (3) diffuse involvement and (4) 'salt-and-pepper' pattern with innumerable small focal lesions (variegated pattern). After 48 h, cells were exposed to PEITC (10mM) for 18 h and percentage of apoptotic nuclei was measured by cell permeabilization and staining with propidium iodide, in flow cytometry, as described. 6 (b) Adenoviral constructs were generated using the BD Adeno-X Expression Systems 2 (BD Biosciences-Clontech, Palo Alto, CA, USA). For AdhBAG3 construction, bag3 full-length cDNA from human brain was cloned in pDNR-CMV vector and the gene expression cassette was transferred to the Adenoviral Acceptor Vector pLP-Adeno-X-PRLS viral DNA, containing DE1/DE3 Ad5 genome, by Cre-loxP-mediated recombination. AdNull, devoid of bag3 cDNA, was used as a control. K562 were transduced with AdhBAG3 or with control AdNull using a multiplicity of infection of 100 (100 MOI); after 48 h cells were exposed to PEITC at the indicated concentrations for 18 h, then apoptosis was measured by flow cytometry. Graph depicts the percentages of apoptotic nuclei. Significance between two groups was calculated by Student's t-test. For western blot analysis, whole-cell lysates were obtained and analyzed for BAG3 content. GAPDH was assessed to verify equal loading conditions. (c) K562 were transfected with WT1 RNAi or a scrambled sequence; after 24 h cells were transduced with AdhBAG3 or AdNull and, after additional 24 h, exposed to PEITC (10 mM) for 18 h. The graph depicts the percentage increase in cell survival with respect to WT1 RNAi-treated cells.
